Stock listing

Tokyo:4884 Kringle Pharma, Inc. (クリングルファーマ) 株価

Follow Kringle Pharma, Inc. into a list and get an email when it puts out news.

Kringle Pharma, Inc. logo
Ticker
Tokyo:4884
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Tokyo
Currency
JPY

What changed lately

Latest news

Kringle Pharma Announces IND Submission to the U.S. FDA for Oremepermin Alfa for the Treatment of Acute Spinal Cord Injury

Sep 24, 2026

Financial Results for the Nine Months Ended June 30, 2026 [Japanese GAAP] (Non-consolidated)

Aug 10, 2026

Kringle Pharma Advances the Registrational Program for Oremepermin Alfa in Japan with Initiation of Additional Phase 3 in Acute Spinal Cord Injury

Jul 23, 2026

Update on the Investigator-initiated Phase 2 Study in Patients with ALS

Aug 12, 2022

Kringle Pharma Files Patent Application for Treatment of Chronic Spinal Cord Injury

Mar 11, 2022

Kringle Pharma Appoints Hideyuki Okano, M.D., Ph.D. as Scientific Advisor

Feb 28, 2022

Financial Results for the Three Months Ended December 31, 2021(Non-consolidated)

Feb 27, 2022

Kringle Pharma Strengthens IP Portfolio with the Formulation Patent in Europe.

Dec 29, 2021

［Delayed］Financial Results for the Fiscal Year Ended September 30, 2021 (Non-consolidated)

Dec 16, 2021

Last Patient Out in Phase 2 Study of KP-100IT for the Treatment of ALS

Dec 8, 2021

All Kringle Pharma, Inc. news

Kringle Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 11 in all · newest Sep 24, 2026 · oldest 2021

Log in to ask 6ix AI your own questions about Kringle Pharma, Inc.